INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Sarepta Therapeutics, Inc.

LOS ANGELES--(BUSINESS WIRE)--

Glancy Binkow & Goldberg LLP reminds investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) SRPT that purchasers of Sarepta securities between April 21, 2014 and October 27, 2014, inclusive (the “Class Period”), have until February 6, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of Massachusetts.

Sarepta is engaged in the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company's lead product candidate is eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy.

The Complaint alleges that defendants made false and/or misleading statements and/or failed to disclose to investors that: (1) the Company failed to provide sufficient data for its New Drug Application (“NDA”) for marketing approval of eteplirsen; (2) as a result, the Company's NDA for eteplirsen would likely be filed in mid-2015, rather than the end of 2014; and (3), the Company's statements about Sarepta's business, operations and prospects, including statements about eteplirsen's prospects for FDA approval for the treatment of Duchenne muscular dystrophy, were materially false and misleading and/or lacked a reasonable basis.

On October 27, 2014, the Company announced a regulatory update concerning discussions with the U.S. Food and Drug Administration related to Sarepta's NDA for eteplirsen. According to the Company, following a Pre-NDA meeting in September 2014, the FDA provided updated guidance regarding additional data required as part of, or at the time of, the NDA submission, including: (i) minimum duration of safety in new patients exposed to eteplirsen; (ii) patient-level natural history data from independent academic institutions; and (iii) MRI data from a recent study conducted by an independent academic group. Following this news, Sarepta shares declined more than 32%, or $7.65 per share, to close at $15.91 per share on October 27, 2014, on volume of more than 15 million shares.

If you are a member of the Class described above, you may move the Court no later than February 6, 2015, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Casey Sadler, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 201-9150, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.